Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project

被引:15
|
作者
de Wilde, Arno [1 ]
Ossenkoppele, Rik [1 ,2 ,3 ]
Pelkmans, Wiesje [1 ]
Bouwman, Femke [1 ]
Groot, Colin [1 ,2 ]
van Maurik, Ingrid [1 ]
Zwan, Marissa [1 ]
Yaqub, Maqsood [2 ]
Barkhof, Frederik [2 ,4 ,5 ]
Lammertsma, Adriaan A. [2 ]
Biessels, Geert Jan [6 ]
Scheltens, Philip [1 ]
van Berckel, Bart N. [1 ,2 ]
van der Flier, Wiesje M. [1 ,7 ]
机构
[1] Vrije Univ Amsterdam, Amsterdam UMC, Alzheimer Ctr, Dept Neurol,Amsterdam Neurosci, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Amsterdam UMC, Amsterdam Neurosci, Dept Radiol & Nucl Med, Amsterdam, Netherlands
[3] Lund Univ, Clin Memory Res Unit, Malmo, Sweden
[4] UCL, Inst Neurol, London, England
[5] UCL, Inst Healthcare Engn, London, England
[6] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol & Neurosurg, Utrecht, Netherlands
[7] Vrije Univ Amsterdam, Amsterdam Neurosci, Dept Epidemiol & Biostat, Amsterdam, Netherlands
关键词
Alzheimer's disease; Amyloid; Positron emission tomography; Appropriate use criteria; Dementia; Clinical practice; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS ASSOCIATION WORKGROUPS; NATIONAL INSTITUTE; DIAGNOSTIC GUIDELINES; TASK-FORCE; DISEASE; RECOMMENDATIONS; BIOMARKERS; DEMENTIA; MANAGEMENT;
D O I
10.1016/j.jalz.2019.07.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: The objective of this study was to assess the usefulness of the appropriate use criteria (AUC) for amyloid imaging in an unselected cohort. Methods: We calculated sensitivity and specificity of appropriate use (increased confidence and management change), as defined by Amyloid Imaging Taskforce in the AUC, and other clinical utility outcomes. Furthermore, we compared differences in post-positron emission tomography diagnosis and management change between "AUC-consistent" and "AUC-inconsistent" patients. Results: Almost half (250/507) of patients were AUC-consistent. In both AUC-consistent and AUC-inconsistent patients, post-positron emission tomography diagnosis (28%-21%) and management (32%-17%) change was substantial. The Amyloid Imaging Taskforce's definition of appropriate use occurred in 55/507 (13%) patients, detected by the AUC with a sensitivity of 93%, and a specificity of 56%. Diagnostic changes occurred independently of AUC status (sensitivity: 57%, specificity: 53%). Discussion: The current AUC are not sufficiently able to discriminate between patients who will benefit from amyloid positron emission tomography and those who will not. (C) 2019 The Authors. Published by Elsevier Inc.
引用
收藏
页码:1458 / 1467
页数:10
相关论文
共 50 条
  • [31] Concordance Between Cerebrospinal Fluid Biomarkers and [11C] PIB PET in a Memory Clinic Cohort
    Zwan, Marissa
    van Harten, Argonde
    Ossenkoppele, Rik
    Bouwman, Femke
    Teunissen, Charlotte
    Adriaanse, Sofie
    Lammertsma, Adriaan
    Scheltens, Philip
    van Berckel, Bart
    van der Flier, Wiesje
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 41 (03) : 801 - 807
  • [32] Plasma biomarkers of amyloid, tau, astrogliosis, and axonal injury in a mixed memory clinic cohort
    Gleerup, Helena Sophia
    Simonsen, Anja Hviid
    Grotschel, Lana
    Gramkow, Mathias Holsey
    Hogh, Peter
    Blennow, Kaj
    Zetterberg, Henrik
    Ashton, Nicholas
    Hasselbalch, Steen Gregers
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2025, 17 (01)
  • [33] Benzodiazepine use and brain amyloid load in nondemented older individuals: a florbetapir PET study in the Multidomain Alzheimer Preventive Trial cohort
    Desmidt, Thomas
    Delrieu, Julien
    Lebouvier, Thibaud
    Robert, Gabriel
    David, Renaud
    Balageas, Anna-Chloe
    Surget, Alexandre
    Belzung, Catherine
    Arlicot, Nicolas
    Ribeiro, Maria-Joao
    Payoux, Pierre
    Vellas, Bruno
    El-Hage, Wissam
    Tavernier, Elsa
    Camus, Vincent
    Guyonnet, Sophie
    Carrie, Isabelle
    Brigitte, Laureane
    Lala, Francoise
    Delrieu, Julien
    Villars, Helene
    Combrouze, Emeline
    Badufle, Carole
    Zueras, Audrey
    Andrieu, Sandrine
    Cantet, Christelle
    Morin, Christophe
    Van Kan, Gabor Abellan
    Dupuy, Charlotte
    Rolland, Yves
    Caillaud, Celine
    Ousset, Pierre-Jean
    Lala, Francoise
    Andrieu, Sandrine
    Cantet, Christelle
    Coley, Nicola
    NEUROBIOLOGY OF AGING, 2019, 84 : 61 - 69
  • [34] Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association
    Johnson, Keith A.
    Minoshima, Satoshi
    Bohnen, Nicolaas I.
    Donohoe, Kevin J.
    Foster, Norman L.
    Herscovitch, Peter
    Karlawish, Jason H.
    Rowe, Christopher C.
    Carrillo, Maria C.
    Hartley, Dean M.
    Hedrick, Saima
    Pappas, Virginia
    Thies, William H.
    ALZHEIMERS & DEMENTIA, 2013, 9 (01) : E1 - E16
  • [35] Computerized decision support is an effective approach to select memory clinic patients for amyloid-PET
    Rhodius-Meester, Hanneke F. M.
    van Maurik, Ingrid S.
    Collij, Lyduine E.
    van Gils, Aniek M.
    Koikkalainen, Juha
    Tolonen, Antti
    Pijnenburg, Yolande A. L.
    Berkhof, Johannes
    Barkhof, Frederik
    van de Giessen, Elsmarieke
    Lotjonen, Jyrki
    van der Flier, Wiesje M.
    PLOS ONE, 2024, 19 (05):
  • [36] Predicting amyloid-PET status in a memory clinic: The role of the novel antero-posterior index and visual rating scales
    Zilioli, Alessandro
    Misirocchi, Francesco
    Pancaldi, Beatrice
    Mutti, Carlotta
    Ganazzoli, Chiara
    Morelli, Nicola
    Pellegrini, Francesca Ferrari
    Messa, Giovanni
    Scarlattei, Maura
    Mohanty, Rosaleena
    Ruffini, Livia
    Westman, Eric
    Spallazzi, Marco
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [37] Appropriate use criteria for dementia amyloid imaging in Switzerland - mini-review and statement on behalf of the Swiss Society of Nuclear Medicine and the Swiss Memory Clinics
    Juengling, Freimut Dankwart
    Allenbach, Gilles
    Bruehlmeier, Matthias
    Klaeser, Bernd
    Wissmeyer, Michael Peter
    Garibotto, Valentina
    Felbecker, Ansgar
    Georgescu, Dan
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2021, 60 (01): : 7 - 9
  • [38] Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
    Collij, Lyduine E.
    Farrar, Gill
    Zwan, Marissa
    van de Giessen, Elsmarieke
    Ossenkoppele, Rik
    Barkhof, Frederik
    Rozemuller, Annemieke J. M.
    Pijnenburg, Yolande A. L.
    van der Flier, Wiesje M.
    Bouwman, Femke
    ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)
  • [39] Comparison between amyloid-PET and CSF amyloid-β biomarkers in a clinical cohort with memory deficits
    Bouter, Caroline
    Vogelgsang, Jonathan
    Wiltfang, Jens
    CLINICA CHIMICA ACTA, 2019, 492 : 62 - 68
  • [40] The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP-TAU study
    Vermeiren, Marie R.
    Somsen, Joost
    Luurtsema, Gert
    Reesink, Fransje E.
    Verwey, Nicolaas A.
    Hempenius, Liesbeth
    Tolboom, Nelleke
    Biessels, Geert Jan
    Biesbroek, J. Matthijs
    Vernooij, Meike W.
    van Zanten, Sophie E. M. Veldhuijzen
    Seelaar, Harro
    Coomans, Emma M.
    Teunissen, Charlotte E.
    Lemstra, Afina W.
    van Harten, Argonde C.
    Visser, Leonie N. C.
    van der Flier, Wiesje M.
    van de Giessen, Elsmarieke
    Ossenkoppele, Rik
    ALZHEIMERS RESEARCH & THERAPY, 2024, 16 (01)